165 related articles for article (PubMed ID: 20951500)
21. Autonomic dysfunction with mutations in the gene that encodes methyl-CpG-binding protein 2: insights into Rett syndrome.
Lioy DT; Wu WW; Bissonnette JM
Auton Neurosci; 2011 Apr; 161(1-2):55-62. PubMed ID: 21316312
[TBL] [Abstract][Full Text] [Related]
22. Behavioral and anatomical abnormalities in Mecp2 mutant mice: a model for Rett syndrome.
Stearns NA; Schaevitz LR; Bowling H; Nag N; Berger UV; Berger-Sweeney J
Neuroscience; 2007 May; 146(3):907-21. PubMed ID: 17383101
[TBL] [Abstract][Full Text] [Related]
23. Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome.
Tsai SJ
Med Hypotheses; 2007; 68(5):1144-6. PubMed ID: 16996699
[TBL] [Abstract][Full Text] [Related]
24. Cell-specific expression of wild-type MeCP2 in mouse models of Rett syndrome yields insight about pathogenesis.
Alvarez-Saavedra M; Sáez MA; Kang D; Zoghbi HY; Young JI
Hum Mol Genet; 2007 Oct; 16(19):2315-25. PubMed ID: 17635839
[TBL] [Abstract][Full Text] [Related]
25. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
Gadalla KK; Bailey ME; Cobb SR
Biochem J; 2011 Oct; 439(1):1-14. PubMed ID: 21916843
[TBL] [Abstract][Full Text] [Related]
26. Exploring the possible link between MeCP2 and oxidative stress in Rett syndrome.
Filosa S; Pecorelli A; D'Esposito M; Valacchi G; Hajek J
Free Radic Biol Med; 2015 Nov; 88(Pt A):81-90. PubMed ID: 25960047
[TBL] [Abstract][Full Text] [Related]
27. Peripheral administration of brain-derived neurotrophic factor to Rett syndrome animal model: a possible approach for the treatment of Rett syndrome.
Tsai SJ
Med Sci Monit; 2012 Aug; 18(8):HY33-36. PubMed ID: 22847207
[TBL] [Abstract][Full Text] [Related]
28. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome.
Asaka Y; Jugloff DG; Zhang L; Eubanks JH; Fitzsimonds RM
Neurobiol Dis; 2006 Jan; 21(1):217-27. PubMed ID: 16087343
[TBL] [Abstract][Full Text] [Related]
29. Identification of cis-regulatory elements for MECP2 expression.
Liu J; Francke U
Hum Mol Genet; 2006 Jun; 15(11):1769-82. PubMed ID: 16613900
[TBL] [Abstract][Full Text] [Related]
30. Spectrum of MECP2 mutations in New Zealand Rett syndrome patients.
Raizis AM; Saleem M; MacKay R; George PM
N Z Med J; 2009 Jun; 122(1296):21-8. PubMed ID: 19652677
[TBL] [Abstract][Full Text] [Related]
31. MeCP2 mutant protein is expressed in astrocytes as well as in neurons and localizes in the nucleus.
Kifayathullah LA; Arunachalam JP; Bodda C; Agbemenyah HY; Laccone FA; Mannan AU
Cytogenet Genome Res; 2010; 129(4):290-7. PubMed ID: 20625242
[TBL] [Abstract][Full Text] [Related]
32. Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome.
Medrihan L; Tantalaki E; Aramuni G; Sargsyan V; Dudanova I; Missler M; Zhang W
J Neurophysiol; 2008 Jan; 99(1):112-21. PubMed ID: 18032561
[TBL] [Abstract][Full Text] [Related]
33. MECP2 mutations in Serbian Rett syndrome patients.
Djarmati A; Dobricić V; Kecmanović M; Marsh P; Jancić-Stefanović J; Klein C; Djurić M; Romac S
Acta Neurol Scand; 2007 Dec; 116(6):413-9. PubMed ID: 17986102
[TBL] [Abstract][Full Text] [Related]
34. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome.
Ogier M; Wang H; Hong E; Wang Q; Greenberg ME; Katz DM
J Neurosci; 2007 Oct; 27(40):10912-7. PubMed ID: 17913925
[TBL] [Abstract][Full Text] [Related]
35. Mutations in the MECP2 gene are not a major cause of Rett syndrome-like or related neurodevelopmental phenotype in male patients.
Santos M; Temudo T; Kay T; Carrilho I; Medeira A; Cabral H; Gomes R; Lourenço MT; Venâncio M; Calado E; Moreira A; Oliveira G; Maciel P
J Child Neurol; 2009 Jan; 24(1):49-55. PubMed ID: 19168818
[TBL] [Abstract][Full Text] [Related]
36. [Rett syndrome: clinical and molecular aspects].
Záhoráková D; Zeman J; Martásek P
Cas Lek Cesk; 2007; 146(8):647-52. PubMed ID: 17874730
[TBL] [Abstract][Full Text] [Related]
37. Screening for MECP2 mutations in Spanish patients with an unexplained mental retardation.
Tejada MI; Peñagarikano O; Rodriguez-Revenga L; Martinez-Bouzas C; García B; Bádenas C; Guitart M; Minguez M; García-Alegría E; Sanz-Parra A; Beristain E; Milá M
Clin Genet; 2006 Aug; 70(2):140-4. PubMed ID: 16879196
[TBL] [Abstract][Full Text] [Related]
38. Postnatal changes in serotonergic innervation to the hippocampus of methyl-CpG-binding protein 2-null mice.
Isoda K; Morimoto M; Matsui F; Hasegawa T; Tozawa T; Morioka S; Chiyonobu T; Nishimura A; Yoshimoto K; Hosoi H
Neuroscience; 2010 Feb; 165(4):1254-60. PubMed ID: 19932741
[TBL] [Abstract][Full Text] [Related]
39. MeCP2 expression and function during brain development: implications for Rett syndrome's pathogenesis and clinical evolution.
Kaufmann WE; Johnston MV; Blue ME
Brain Dev; 2005 Nov; 27 Suppl 1():S77-S87. PubMed ID: 16182491
[TBL] [Abstract][Full Text] [Related]
40. Neural development of methyl-CpG-binding protein 2 null embryonic stem cells: a system for studying Rett syndrome.
Okabe Y; Kusaga A; Takahashi T; Mitsumasu C; Murai Y; Tanaka E; Higashi H; Matsuishi T; Kosai K
Brain Res; 2010 Nov; 1360():17-27. PubMed ID: 20816763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
